Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC#Johnson #amp #Johnson039s #TAR200 #monotherapy #achieves #high #diseasefree #survival #percent #BCGunresponsive #highrisk #papillary #NMIBC